Biocardia announces positive dsmb review and recommendation to continue phase iii pivotal cardiamp heart failure study as designed

San carlos, calif., dec. 17, 2020 (globe newswire) -- biocardia (nasdaq: bcda), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent data safety monitoring board (dsmb) has completed its prespecified data review for the phase iii pivotal cardiamp™ heart failure trial. the dsmb based its review on all available data for the 86 patients enrolled in the trial, including 60 randomized patients who have reached their one-year follow-up. the dsmb performed a risk-benefit assessment, indicated no safety concerns, and recommended that the study continue as designed.
BCDA Ratings Summary
BCDA Quant Ranking